These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16787208)

  • 21. New strategy of thrombolysis. Conjunctive effect of plasminogen activators with different pharmacokinetic profile.
    Maksimenko AV
    Ann N Y Acad Sci; 1998 Dec; 864():96-105. PubMed ID: 9928084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
    Gurewich V
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):16B-21B. PubMed ID: 3117859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New strategies in the development of thrombolytic agents.
    Lijnen HR; Collen D
    Curr Stud Hematol Blood Transfus; 1991; (58):69-72. PubMed ID: 1954777
    [No Abstract]   [Full Text] [Related]  

  • 24. Molecular mechanism of action of newer thrombolytic agents.
    Collen D
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrinolytic therapy: biochemical mechanisms.
    Robbins KC
    Semin Thromb Hemost; 1991 Jan; 17(1):1-6. PubMed ID: 1828622
    [No Abstract]   [Full Text] [Related]  

  • 27. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basic mechanisms and regulation of fibrinolysis.
    Longstaff C; Kolev K
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S98-105. PubMed ID: 26149056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The plasminogen (fibrinolytic) system.
    Collen D
    Thromb Haemost; 1999 Aug; 82(2):259-70. PubMed ID: 10605712
    [No Abstract]   [Full Text] [Related]  

  • 31. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrin-specific thrombolytic agents.
    Collen D
    Ann Biol Clin (Paris); 1988; 46(3):195-200. PubMed ID: 3044205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microfluidic Modeling of Thrombolysis.
    Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
    Pieters M; Hekkenberg RT; Barrett-Bergshoeff M; Rijken DC
    Ultrasound Med Biol; 2004 Nov; 30(11):1545-52. PubMed ID: 15588966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrin specificity of plasminogen activators, rebound generation of thrombin, and their therapeutic implications.
    Sobel BE
    Coron Artery Dis; 2001 Jun; 12(4):323-32. PubMed ID: 11428542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R; Li S; Gurewich V
    J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Plasminogen activation and regulation of fibrinolysis].
    Madoiwa S
    Nihon Rinsho; 2014 Jul; 72(7):1218-23. PubMed ID: 25163311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.
    Susawa T; Yui Y; Hattori R; Takatsu Y; Yui N; Takahashi M; Aoyama T; Murohara Y; Shirotani M; Kawai C
    Jpn Circ J; 1988 Jan; 52(1):72-8. PubMed ID: 3129601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.